MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

Oncology Here & Now

OncoAlert’s podcast: the top topics in oncology, discussed by colleagues from around the world.

On the stage: Prostate cancer statistics 2025

Prostate cancer statistics 2025Dr. Gil Morgan with Mr. Tyler KratzerSeason 2, Episode 2

Dr. Gil Morgan with Mr. Tyler Kratzer. Season 2, Episode 2. About this episode: Prostate cancer statistics 2025

Listen onApple PodcastsSpotifyAmazon MusicYouTube

At the table

The hosts. Choose one for the conversations they hosted.

All episodes

Season 2

From September 2025

  1. Prostate cancer statistics 2025

    Rising rates of advanced prostate cancer and persistent disparities call for better early detection and fairer outcomes.

    Dr. Gil Morgan with Mr. Tyler Kratzer. Season 2, Episode 2. September 25, 2025.

  2. The BULLSEYE trial and PSMA radioligands

    The BULLSEYE trial, lutetium and terbium, and follow-up with PSMA PET in prostate cancer.

    Dr. Barbara Melão with Dr. Danny Mena. Season 2, Episode 1. September 7, 2025.

Season 1

March to June 2025

  1. Upper tract urothelial carcinoma

    Upper tract urothelial carcinoma, from risk stratification to management and long-term renal function.

    Dr. Barbara Melão with Dr. Philippe Spiess. Season 1, Episode 6. May 20, 2025.

  2. Annual Report to the Nation on the Status of Cancer

    The latest U.S. data on cancer incidence and mortality, from the Annual Report to the Nation.

    Dr. Gil Morgan with Dr. Ahmedin Jemal. Season 1, Episode 5. April 28, 2025.

  3. First-line therapy in EGFR-mutant NSCLC

    First-line treatment of EGFR-mutant NSCLC: FLAURA, MARIPOSA and FLAURA2, and what comes next.

    Dr. Biagio Ricciuti with Dr. Marcelo Corassa. Season 1, Episode 4. April 14, 2025.

  4. Supportive care and telemedicine

    Telehealth in oncology and palliative care, and how it improves access in remote and underserved areas.

    Dr. Joseph McCollom with Dr. Cristiane Bergerot. Season 1, Episode 3. March 26, 2025.

  5. Adjuvant CDK4/6 inhibitors in breast cancer

    Abemaciclib and ribociclib in the adjuvant treatment of breast cancer, after monarchE and NATALEE.

    Dr. Elisa Agostinetto with Dr. Maryam Lustberg. Season 1, Episode 2. March 14, 2025.

  6. The Advanced Prostate Cancer Consensus Conference

    The origins and evolution of the Advanced Prostate Cancer Consensus Conference, and where it goes in 2026.

    Dr. Silke Gillessen and Dr. Aurelius Omlin. Season 1, Episode 1. March 5, 2025.

OncoAlert Español

In Spanish

  1. Oncología: ahora y en directo

    The first episode of OncoAlert Español: the bladder cancer advances from ESMO 2025, in Spanish.

    Dra. Regina Barragán-Carrillo and Dra. Natalia Gandur. Episodio 1, en español. ESMO 2025.